Type II of ovarian cancer cells has enhanced predisposition toward survival and metastasis

12^th World Cancer Conference

September 26-28, 2016 London, UK

Magdalena Klink

Polish Academy of Sciences in Lodz, Poland

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Epithelial ovarian cancer (EOC) is highly heterogeneous disease with multiple histopathological features and different biological behaviors. EOC is clinically classified into four stages according to FIGO classification. However, results concerning molecular genetic studies with clinical and histopathological findings led to a proposition for a new model of ovarian carcinogenesis. Type I tumors are low-grade and are genetically more stable, while type II tumors are high-grade, rapidly growing, highly aggressive and genetically unstable. Chemotherapeutic agents that are effective against type II tumors are not effective for type I tumors. The current challenge aims toward better recognition of ovarian cancer (OC) cellsâ�� features. We compared the ability of type I or type II OC cells, isolated from tumor of EOC patients, to release certain factors, which facilitate tumor cell survival, invasion and metastasis. Our studies demonstrated that type II OC cells released higher amount of immunosuppressive interleukin 10, transforming growth factor �² and heat shock protein (HspA1A) during culture, in vitro. When patients were compared according to cancer progression (FIGO classification) the difference in the biological activity of OC cells was observed only at the level of interleukin 10 release. We did not find any difference in the ability of OC cells to secrete pro-inflammatory cytokines (interleukin 6, interleukin 8), regardless of the type of ovarian cancer and stage of disease. In this study, we found that OC cells of patients with type II tumor demonstrated more intense activity in regards to survival and metastasis, which should be considered during therapy.

Biography :

Email: mklink@cbm.pan.pl